drugset / Trial / NCT00005949
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
NaSingle-groupOpen-labelTreatment
Summary
Phase II trial to study the effectiveness of vaccine therapy plus interleukin-2 in treating patients who have advanced melanoma. Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Melanoma vaccine plus interleukin-2 may kill more cancer cells
Timeline
- Start
- 2001-03
- Primary completion
- 2006-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |
| Subject | gp100:209-217(210M) | Peptide | — | Subcutaneous |